Overview
Overview
Parent Cell: Akira Natural Killer Cells derived from UCT-WJ-MSC lineage differentiation | Cytotoxic and immunosurveillance exosomes for cancer immunotherapy, viral infection control, and senescent cell clearance in anti-aging protocols
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| 110 Billion Exosomes / 1 mL vial |
| Granzyme B and Perforin confirmed by ELISA |
| FasL expression confirmed by Western blot |
| NTA mean size 80–120 nm |
| Stored at −80°C |
Definition
What Are Exosomes?
Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.
Process
Mechanism of Action & Molecular Cargo
Tumor Cell Apoptosis via Granzyme B/Perforin: NK exosomes deliver granzyme B (serine protease) through perforin-created pores in target cell membranes, initiating caspase cascade and apoptosis in tumor cells — without requiring live NK cell contact or MHC matching.
Fas/FasL Apoptosis Pathway: FasL expressed on NK exosome surfaces engages Fas (CD95) receptor on Fas-expressing tumor and senescent cells, activating the extrinsic apoptosis pathway — complementary to granzyme/perforin killing.
TRAIL-Mediated Killing: TRAIL (TNF-related apoptosis-inducing ligand) carried on NK exosome membranes selectively induces apoptosis in TRAIL-sensitive tumor cells, sparing normal cells — a critical safety advantage.
Immune Reconstitution: IFN-γ mRNA and miR-155/miR-223 cargo activates natural killer and cytotoxic T-cell function in the tumor microenvironment — amplifying host anti-tumor immunity beyond exosome-mediated direct killing.
Senescent Cell Clearance: ULBP2+ senescent cells are selectively targeted by NKG2D ligand recognition on NK exosome membrane — enabling selective elimination of SASP-producing senescent cells without damage to proliferating cells.
Biomarkers
Key Molecular Cargo
| Molecule / miRNA | Therapeutic Function |
|---|---|
| Granzyme B | Serine protease delivered via perforin pores; caspase-dependent apoptosis |
| Perforin | Pore-forming protein in target cell membrane; granzyme delivery |
| FasL (CD178) | Extrinsic apoptosis pathway activation via Fas receptor engagement |
| TRAIL | TNF-related apoptosis-inducing ligand; selective tumor cell killing |
| IFN-γ mRNA | Immune activation cytokine; enhances host anti-tumor NK and CTL function |
| miR-155 / miR-223 | NK cell activation miRNAs; immunomodulatory exosomal cargo |
| NKG2D (membrane) | Senescent cell receptor — NKG2DL recognition for selective clearance |
Applications
Therapeutic Applications
- Hematologic Malignancies (AML, ALL, CLL, Lymphoma)
- Solid Tumors (Lung, Breast, Liver, Prostate, Colorectal, Pancreatic)
- Viral Infections (HIV, Hepatitis B/C, HPV, CMV, EBV)
- Anti-Aging Senolytic Protocol — senescent cell clearance
- Post-cancer immune reconstitution
- Autoimmune Hepatitis / Scleroderma — NK immunomodulation
- CAR-NK combination platform
- Immune Surveillance Deficiency
Evidence
Clinical & Preclinical Evidence
A 2024 review confirmed NK exosomes contain granzyme B, perforin, FasL, and TRAIL capable of inducing apoptosis in tumor cells in vitro and in vivo — with efficacy demonstrated against leukemia, lymphoma, and solid tumor lines. The cell-free format provides superior scalability, shelf stability, and safety vs live NK cell infusion.[1]
NK exosomes derived from umbilical cord blood NK cells demonstrated 65–75% tumor lysis in K562 (CML) and Raji (Burkitt lymphoma) cell lines at 50 μg protein dose — confirming potent cytotoxic activity.[2]
In senescence clearance studies, NK-derived vesicles selectively eliminated p21+/NKG2DL+ senescent fibroblasts at 3× higher efficiency vs non-senescent cells — validating the anti-aging senolytic application.
A 2023 review confirmed that NK exosomes can be engineered to express targeted CAR constructs (CD19-CAR, HER2-CAR) on their surface, enabling next-generation tumor-specific NK exosome therapy — a development pathway available with Akira NK Exosomes as the starting material.[3]